Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Operating Income (2016 - 2025)

Historic Operating Income for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.4 million.

  • Lipocine's Operating Income fell 2777.32% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.3 million, marking a year-over-year decrease of 1919.65%. This contributed to the annual value of -$1.2 million for FY2024, which is 9355.84% up from last year.
  • Lipocine's Operating Income amounted to -$3.4 million in Q3 2025, which was down 2777.32% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Lipocine's Operating Income registered a high of $12.8 million during Q4 2021, and its lowest value of -$7.0 million during Q3 2023.
  • Over the past 5 years, Lipocine's median Operating Income value was -$3.0 million (recorded in 2021), while the average stood at -$1.9 million.
  • In the last 5 years, Lipocine's Operating Income soared by 36623.94% in 2021 and then crashed by 16486.16% in 2025.
  • Lipocine's Operating Income (Quarter) stood at $12.8 million in 2021, then plummeted by 120.03% to -$2.6 million in 2022, then decreased by 1.27% to -$2.6 million in 2023, then soared by 159.59% to $1.5 million in 2024, then plummeted by 317.48% to -$3.4 million in 2025.
  • Its Operating Income stands at -$3.4 million for Q3 2025, versus -$2.4 million for Q2 2025 and -$2.1 million for Q1 2025.